Regarding some reports about our company
July 18, 2024
Recently, some media outlets have published articles about our company.
This article concerns a medical institution to which our company received a manufacturing contract for disease treatment and provided cells, and to which the medical institution received a report of illness from a patient. The medical institution reported the incident to the Certification Committee (Safety Future Certified Regenerative medicine Committee), and although the patient's symptoms were temporary and the patient has recovered, our company also takes this as an important caution. Under the guidance of the Certification Committee, and in accordance with the Act on Ensuring the Safety of Regenerative medicine we have worked in cooperation with the medical institution to raise awareness and gather information, and have been diligently working to determine the cause. Subsequently, the Certification Committee conducted an investigation, deliberation, and judgment regarding safety, and on June 18, 2024 (Tuesday), the following conclusion was reached.
Conclusion of the Certification Committee
Medical institutions will be required to submit an application for a change review regarding disease reports, which will include information about changes in administration methods and the risks of DMSO in the "informed information document."
Furthermore, ROHTO Pharmaceutical Co., Ltd., Ltd. will be requested to provide warnings to all facilities that supply its products regarding the risks and administration methods of DMSO.
Based on the above conclusion, we will proactively issue warnings to all medical facilities that supply our products.
Rohto Pharmaceutical has been undertaking contract work under the Act on Ensuring the Safety of Regenerative medicine etc., with the desire to contribute to patients in need using the technology cultivated through the development of regenerative Regenerative medicine products, and to deliver this technology as quickly as possible. Moving forward, we will continue to work even harder in cooperation with medical institutions to expand treatment options for patients suffering from diseases.